Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium in vivo models of osteosarcoma

Douglas Harrison; Jonathan Gill; Michael Roth; Pooja Hingorani; Wendong Zhang; Beverly Teicher; Eric Earley; Stephen Erickson; Gregory Gatto; Raushan Kumasheva; Peter Houghton; Malcolm Smith; E. Anders Kolb; Richard Gorlick

doi:10.1002/pbc.30017

Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium in vivo models of osteosarcoma

Douglas Harrison, Jonathan Gill, Michael Roth, Pooja Hingorani, Wendong Zhang, Beverly Teicher, Eric Earley, Stephen Erickson, Gregory Gatto, Raushan Kumasheva, Peter Houghton, Malcolm Smith, E. Anders Kolb, Richard Gorlick

Pediatrics

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Copanlisib is a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor, with activity against all four PI3K class I isoforms (PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ). Whole-genome and RNA sequencing data have revealed several PI3K aberrations in osteosarcoma tumor samples. The in vivo anticancer effects of copanlisib were assessed in a panel of six osteosarcoma models. Copanlisib induced prolonged event-free survival in five of six osteosarcoma models; however, all models demonstrated progressive disease suggesting minimal activity. While copanlisib did not result in tumor regression, more data are needed to fully explore the role of the PI3K pathway in the pathogenesis of osteosarcoma.

Original language	English (US)
Article number	e30017
Journal	Pediatric Blood and Cancer
Volume	70
Issue number	1
DOIs	https://doi.org/10.1002/pbc.30017
State	Published - Jan 2023

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.30017

Cite this

Harrison, D., Gill, J., Roth, M., Hingorani, P., Zhang, W., Teicher, B., Earley, E., Erickson, S., Gatto, G., Kumasheva, R., Houghton, P., Smith, M., Anders Kolb, E., & Gorlick, R. (2023). Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium in vivo models of osteosarcoma. Pediatric Blood and Cancer, 70(1), Article e30017. https://doi.org/10.1002/pbc.30017

Harrison, D , Gill, J , Roth, M, Hingorani, P, Zhang, W, Teicher, B, Earley, E, Erickson, S, Gatto, G, Kumasheva, R, Houghton, P, Smith, M, Anders Kolb, E & Gorlick, R 2023, 'Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium in vivo models of osteosarcoma', Pediatric Blood and Cancer, vol. 70, no. 1, e30017. https://doi.org/10.1002/pbc.30017

@article{19140f4b47044aeab7b75bdff5a48380,

title = "Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium in vivo models of osteosarcoma",

abstract = "Copanlisib is a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor, with activity against all four PI3K class I isoforms (PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ). Whole-genome and RNA sequencing data have revealed several PI3K aberrations in osteosarcoma tumor samples. The in vivo anticancer effects of copanlisib were assessed in a panel of six osteosarcoma models. Copanlisib induced prolonged event-free survival in five of six osteosarcoma models; however, all models demonstrated progressive disease suggesting minimal activity. While copanlisib did not result in tumor regression, more data are needed to fully explore the role of the PI3K pathway in the pathogenesis of osteosarcoma.",

author = "Douglas Harrison and Jonathan Gill and Michael Roth and Pooja Hingorani and Wendong Zhang and Beverly Teicher and Eric Earley and Stephen Erickson and Gregory Gatto and Raushan Kumasheva and Peter Houghton and Malcolm Smith and {Anders Kolb}, E. and Richard Gorlick",

note = "Publisher Copyright: {\textcopyright} 2022 Wiley Periodicals LLC.",

year = "2023",

month = jan,

doi = "10.1002/pbc.30017",

language = "English (US)",

volume = "70",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "1",

}

TY - JOUR

T1 - Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium in vivo models of osteosarcoma

AU - Harrison, Douglas

AU - Gill, Jonathan

AU - Roth, Michael

AU - Hingorani, Pooja

AU - Zhang, Wendong

AU - Teicher, Beverly

AU - Earley, Eric

AU - Erickson, Stephen

AU - Gatto, Gregory

AU - Kumasheva, Raushan

AU - Houghton, Peter

AU - Smith, Malcolm

AU - Anders Kolb, E.

AU - Gorlick, Richard

PY - 2023/1

Y1 - 2023/1

N2 - Copanlisib is a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor, with activity against all four PI3K class I isoforms (PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ). Whole-genome and RNA sequencing data have revealed several PI3K aberrations in osteosarcoma tumor samples. The in vivo anticancer effects of copanlisib were assessed in a panel of six osteosarcoma models. Copanlisib induced prolonged event-free survival in five of six osteosarcoma models; however, all models demonstrated progressive disease suggesting minimal activity. While copanlisib did not result in tumor regression, more data are needed to fully explore the role of the PI3K pathway in the pathogenesis of osteosarcoma.

AB - Copanlisib is a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor, with activity against all four PI3K class I isoforms (PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ). Whole-genome and RNA sequencing data have revealed several PI3K aberrations in osteosarcoma tumor samples. The in vivo anticancer effects of copanlisib were assessed in a panel of six osteosarcoma models. Copanlisib induced prolonged event-free survival in five of six osteosarcoma models; however, all models demonstrated progressive disease suggesting minimal activity. While copanlisib did not result in tumor regression, more data are needed to fully explore the role of the PI3K pathway in the pathogenesis of osteosarcoma.

UR - http://www.scopus.com/inward/record.url?scp=85139826963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85139826963&partnerID=8YFLogxK

U2 - 10.1002/pbc.30017

DO - 10.1002/pbc.30017

M3 - Article

C2 - 36250964

AN - SCOPUS:85139826963

SN - 1545-5009

VL - 70

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 1

M1 - e30017

ER -

Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium in vivo models of osteosarcoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this